, Tracking Stock Market Picks
Enter Symbol:
Rating: THLDD

THRESHOLD PHARMACEUT (NASDAQ: THLD) downgraded to Neutral by Piper Jaffray

Monday,  Dec 7, 2015  5:25 PM ET by Kristen Bailey

Piper Jaffray downgraded THRESHOLD PHARMACEUT (NASDAQ: THLD) to Neutral.
Piper Jaffray rated THRESHOLD PHARMACEUT (NASDAQ: THLD) to Overweight on 02/20/2013, when the price was $4.95.

Threshold is focused on the discovery, development, and commercialization of small molecule therapeutics based on `Metabolic Targeting.` This approach targets abnormal glucose metabolism - a fundamental property of most solid tumors and other diseases. The company's initial focus is the treatment of cancer and benign prostatic hyperplasia, a disease characterized by overgrowth of the prostate.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy